Is GPNMB the Achilles' Heel of Mo-MDSC While Marking Their Suppressive Activity?

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Mario P Colombo

Abstract

Glycoprotein nonmetastatic B/DC-Hil/Osteoactivin on myeloid-derived suppressor cells impairs T lymphocytes through the binding of Syndecan-4, delineating a new checkpoint pair to be targeted perhaps in combination with PD-1/PD-L1 blockage.See related article by Kobayashi et al., p. 828.

References

May 17, 2017·Oncoimmunology·Annkristin HeinePeter Brossart
Nov 11, 2017·Frontiers in Immunology·Maria Laura CostaMarina Cella
Jul 28, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Masato KobayashiKiyoshi Ariizumi

❮ Previous
Next ❯

Citations

Jul 10, 2019·Frontiers in Immunology·Sabina SangalettiMario P Colombo
May 3, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter Brossart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

The Journal of Bone and Joint Surgery. American Volume
D B Kettelkamp
Nature
B Vogelstein, K W Kinzler
Oncotarget
George Sflomos, Cathrin Brisken
© 2022 Meta ULC. All rights reserved